<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Arcus Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/arcus-biosciences-inc</link>
<description>Latest news and press releases for Arcus Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/arcus-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b62b78dffbe2df113f67.webp</url>
<title>Arcus Biosciences Inc</title>
<link>https://6ix.com/company/arcus-biosciences-inc</link>
</image>
<item>
<title>Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-to-host-conference-call-to-discuss-first-quarter-2026-financial-results-and-pipeline-updates</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-to-host-conference-call-to-discuss-first-quarter-2026-financial-results-and-pipeline-updates</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., April 21, 2026--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Tuesday, May 5, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline updates for the quarter ended March 31st, 2026.</description>
</item>
<item>
<title>Arcus Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides a Pipeline Update</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-pipeline-update</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-pipeline-update</guid>
<pubDate>Wed, 25 Feb 2026 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., February 25, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, today reported financial results for the year and quarter ended December 31, 2025, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs.</description>
</item>
<item>
<title>Arcus Presents New Data for its HIF-2a Inhibitor Casdatifan, Which Showed Progression-Free Survival Beyond One Year in Late-Line Kidney Cancer</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-presents-new-data-for-its-hif-2a-inhibitor-casdatifan-which-showed-progression-free-survival-beyond-one-year-in-late-line-kidney-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-presents-new-data-for-its-hif-2a-inhibitor-casdatifan-which-showed-progression-free-survival-beyond-one-year-in-late-line-kidney-cancer</guid>
<pubDate>Mon, 23 Feb 2026 22:00:00 GMT</pubDate>
<description>HAYWARD, Calif., February 23, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a pos</description>
</item>
<item>
<title>Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2025 Financial Results and Pipeline Updates</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-host-conference-call-210500087</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-host-conference-call-210500087</guid>
<pubDate>Wed, 11 Feb 2026 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., February 11, 2026--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will host a conference call and webcast on Wednesday, February 25th, 2026 at 1:30 PM PT / 4:30 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter and year ended D</description>
</item>
<item>
<title>Arcus Biosciences Announces New Employment Inducement Grants</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-employment-inducement-213500677</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-employment-inducement-213500677</guid>
<pubDate>Mon, 26 Jan 2026 21:35:00 GMT</pubDate>
<description>HAYWARD, Calif., January 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 16,650 shares of the Company’s common stock at an exercise price per share of $22.13, which was</description>
</item>
<item>
<title>Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-outlines-2026-plans-casdatifan-210500386</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-outlines-2026-plans-casdatifan-210500386</guid>
<pubDate>Wed, 07 Jan 2026 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., January 07, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today outlined its 2026 priorities for casdatifan and its emerging inflammation and immunology (I&I) programs.</description>
</item>
<item>
<title>Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-44th-annual-210500947</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-44th-annual-210500947</guid>
<pubDate>Thu, 18 Dec 2025 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., December 18, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Wednesday, January 14th, 2026, at 3:00 pm PT.</description>
</item>
<item>
<title>Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-provides-phase-3-star-133000124</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-provides-phase-3-star-133000124</guid>
<pubDate>Fri, 12 Dec 2025 13:30:00 GMT</pubDate>
<description>HAYWARD, Calif., December 12, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead Sciences, Inc., due to futility. The decision is based on the recommendation from the Independent Data Monitoring Committee (IDMC</description>
</item>
<item>
<title>Arcus Biosciences to Participate in Two Upcoming Investor Conferences</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-two-upcoming-210500976</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-two-upcoming-210500976</guid>
<pubDate>Tue, 18 Nov 2025 21:05:00 GMT</pubDate>
<description>HAYWARD, Calif., November 18, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in December:</description>
</item>
<item>
<title>Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-pricing-250-033500488</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-pricing-250-033500488</guid>
<pubDate>Fri, 31 Oct 2025 03:35:00 GMT</pubDate>
<description>HAYWARD, Calif., October 31, 2025--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced the pricing of an underwritten public offering of 13,700,000 shares of its common stock at a price to the public of $18.25 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250 million, be</description>
</item>
<item>
<title>Arcus Biosciences Announces Commencement of Public Offering of Common Stock</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-commencement-public-200100816</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-announces-commencement-public-200100816</guid>
<pubDate>Thu, 30 Oct 2025 20:01:00 GMT</pubDate>
<description>HAYWARD, Calif., October 30, 2025--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today announced that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences intends to grant the underwriters a 30-day</description>
</item>
<item>
<title>Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-third-quarter-200500308</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-third-quarter-200500308</guid>
<pubDate>Tue, 28 Oct 2025 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., October 28, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, inflammatory and autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules and discovery programs.</description>
</item>
<item>
<title>Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/taiho-pharmaceutical-exercises-option-exclusive-230000044</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/taiho-pharmaceutical-exercises-option-exclusive-230000044</guid>
<pubDate>Sun, 19 Oct 2025 23:00:00 GMT</pubDate>
<description>TOKYO & HAYWARD, Calif., October 19, 2025--Taiho Pharmaceutical Co., Ltd. ("Taiho") and Arcus Biosciences, Inc. (NYSE:RCUS, "Arcus") announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other territories in Asia (excluding mainland China). This option exercise is based on a 2017 option and lice</description>
</item>
<item>
<title>Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/anti-tigit-domvanalimab-plus-anti-220500438</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/anti-tigit-domvanalimab-plus-anti-220500438</guid>
<pubDate>Sun, 12 Oct 2025 22:05:00 GMT</pubDate>
<description>HAYWARD, Calif., October 12, 2025--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma. The ongoing, multi-arm, global Phase 2 EDGE-Gastric study is evaluat</description>
</item>
<item>
<title>Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-presents-data-hif-120000667</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-presents-data-hif-120000667</guid>
<pubDate>Mon, 06 Oct 2025 12:00:00 GMT</pubDate>
<description>HAYWARD, Calif., October 06, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced new monotherapy data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC). At an investor event hosted later today, the Company will share more detail on these data and preview the expansi</description>
</item>
<item>
<title>Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-host-investor-event-200500850</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-host-investor-event-200500850</guid>
<pubDate>Tue, 02 Sep 2025 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., September 02, 2025--Arcus Biosciences (NYSE:RCUS) announced today that it will host an in-person and virtual Investor Event for analysts and investors on Monday, October 6, 2025, beginning at 10:00 AM ET, in New York City.</description>
</item>
<item>
<title>Arcus Biosciences to Participate in Three Upcoming Investor Conferences</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-three-upcoming-200500320</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-participate-three-upcoming-200500320</guid>
<pubDate>Wed, 20 Aug 2025 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., August 20, 2025--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in September:</description>
</item>
<item>
<title>Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-second-quarter-200500589</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-reports-second-quarter-200500589</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>HAYWARD, Calif., August 06, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the second quarter ended June 30, 2025, and provided a pipeline update on its clinical-stage investigational molecules across multiple common cancers.</description>
</item>
<item>
<title>Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-quemliclustat-receives-orphan-123000370</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/arcus-biosciences-quemliclustat-receives-orphan-123000370</guid>
<pubDate>Thu, 10 Jul 2025 12:30:00 GMT</pubDate>
<description>HAYWARD, Calif., July 10, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of pancreatic cancer.</description>
</item>
<item>
<title>Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response</title>
<link>https://6ix.com/company/arcus-biosciences-inc/news/initial-data-arc-20-study-144500334</link>
<guid isPermaLink="true">https://6ix.com/company/arcus-biosciences-inc/news/initial-data-arc-20-study-144500334</guid>
<pubDate>Sun, 01 Jun 2025 14:45:00 GMT</pubDate>
<description>HAYWARD, Calif., June 01, 2025--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.</description>
</item>
</channel>
</rss>